Literature DB >> 18976119

Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis.

Timothy N Showalter1, Barry A Siegel, Jeffrey F Moley, Thomas J Baranski, Perry W Grigsby.   

Abstract

PURPOSE: Survival outcomes in patients presenting with well-differentiated thyroid cancer with pulmonary metastasis are variable. The aim of this study was to evaluate prognostic factors for outcome in this patient population.
METHODS: A prospective registry database was searched to identify patients presenting with pulmonary metastasis from well-differentiated thyroid cancer. All patients underwent total thyroidectomy and postoperative I-131 therapy. Cox proportional hazards modeling was performed to evaluate prognostic factors for survival outcomes.
RESULTS: Forty (40) patients were identified with well-differentiated thyroid cancer involving the thyroid and metastatic to cervical lymph nodes and lung at initial diagnosis. The median follow-up was 9.7 years for those alive at last follow-up. Cox proportional hazards modeling evaluated age at diagnosis, gender, primary tumor size, and vascular invasion on cause-specific and progression-free survivals. Age at diagnosis was the only significant independent prognostic factor (p = 0.0035). The 10-year cause-specific survivals were 100% in patient's < or =40 years, compared to 36% for those >40 years (p < 0.0001). The corresponding 10-year progression-free survivals were 69% and 12% (p = 0.0003).
CONCLUSIONS: Patients < or =40 years of age presenting with pulmonary metastasis from well-differentiated thyroid cancer had an excellent prognosis. Older patients have a poor survival outcome. Postoperative I-131 therapy is recommended in all patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976119     DOI: 10.1089/cbr.2008.0501

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

Review 2.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

3.  The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.

Authors:  Iain J Nixon; Monica M Whitcher; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

Review 4.  Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.

Authors:  Valentina Lancellotta; Giuseppe Fanetti; Fabio Monari; Monica Mangoni; Renzo Mazzarotto; Luca Tagliaferri; Carlo Gobitti; Elisa Lodi Rizzini; Sara Talomo; Irene Turturici; Fabiola Paiar; Renzo Corvò; Barbara Alicja Jereczek-Fossa; Vittorio Donato; Federica Vianello
Journal:  Radiol Med       Date:  2022-04-08       Impact factor: 3.469

5.  Prognostic values of thyroid tumours.

Authors:  Suzana Manxhuka-Kerliu; Emine Devolli-Disha; Arsim Gerxhaliu; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Hajdin Thaqi
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

6.  Langerhans' Cell Histiocytosis Masquerading as Metastatic Papillary Thyroid Cancer on F-18 FDG PET/CT: Diagnostic Dilemma Solved by PET/CT-Guided Biopsy.

Authors:  Dharmender Malik; Rajender Kumar; Bhagwant Rai Mittal; Gaurav Parkash; Amanjit Bal; Anish Bhattacharya
Journal:  Nucl Med Mol Imaging       Date:  2018-08-13

7.  Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer.

Authors:  Alexandra Chrisoulidou; Maria Boudina; Athanasios Tzemailas; Eleni Doumala; Pashalia K Iliadou; Frideriki Patakiouta; Kalliopi Pazaitou-Panayiotou
Journal:  Thyroid Res       Date:  2011-07-19

8.  The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).

Authors:  Heng Niu; Jingyu Yang; Kunxian Yang; Yingze Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

9.  Primary pulmonary adenocarcinoma mimicking papillary thyroid carcinoma.

Authors:  Ya-Zhen Zhu; Wei-Ping Li; Zhi-Yuan Wang; Hai-Feng Yang; Qing-Lian He; Hong-Guang Zhu; Guang-Juan Zheng
Journal:  J Cardiothorac Surg       Date:  2013-05-17       Impact factor: 1.637

10.  HORMAD2 methylation-mediated epigenetic regulation of gene expression in thyroid cancer.

Authors:  Qiuyu Lin; Sen Hou; Feng Guan; Chenghe Lin
Journal:  J Cell Mol Med       Date:  2018-07-24       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.